ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NXEN Nexien BioPharma Inc (PK)

0.0056
-0.0001 (-1.75%)
Last Updated: 16:24:45
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nexien BioPharma Inc (PK) USOTC:NXEN OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0001 -1.75% 0.0056 0.0056 0.016 0.0056 0.0056 0.0056 15,238 16:24:45

Form 4 - Statement of changes in beneficial ownership of securities

28/05/2024 4:58pm

Edgar (US Regulatory)


SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Greenberg Richard S

(Last) (First) (Middle)
4340 E KENTUCKY AVE
SUITE 206

(Street)
GLENDALE CO 80246

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEXIEN BIOPHARMA, INC. [ NXEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
05/23/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/23/2024 A 1,000,000 A (1) 7,185,193 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class A Warrant $0.0403 11/24/2020 11/24/2025 common stock 1,062,953 1,062,953 D
Class B Warrant $0.0433 11/24/2020 11/24/2025 common stock 1,062,953 1,062,953 D
Class C Warrant $0.0452 11/24/2020 11/24/2025 common stock 1,062,953 1,062,953 D
Convertible note $0.0376 11/24/2020 06/30/2024 common stock 1,062,953 40,000 D
Options to purchase common stock (right to buy) $0.54 07/25/2018 07/25/2025 common stock 150,000 150,000 D
Options to purchase common stock (right to buy) $0.655 10/26/2018 10/26/2025 common stock 100,000 100,000 D
Options to purchase common stock (right to buy) $0.08 08/19/2020 08/19/2027 common stock 2,500,000 2,500,000 D
Explanation of Responses:
1. Issued in lieu of compensation for services.
Remarks:
Richard S. Greenberg 05/28/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

1 Year Nexien BioPharma (PK) Chart

1 Year Nexien BioPharma (PK) Chart

1 Month Nexien BioPharma (PK) Chart

1 Month Nexien BioPharma (PK) Chart

Your Recent History

Delayed Upgrade Clock